RNA viruses frequently bypass the conventional 5′ cap‐dependent mechanism of translation by employing alternative strategies that enable them to commandeer the host’s translational machinery. A ...

TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when ...

The donation commemorates the launch of TriLink’s first mRNA synthesis kit featuring CleanCap® capping technology, an all-in-one kit with its innovative products in one box at a competitive price.

As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

Hongene Biotech Announces Grant to Expand Global Access to mRNA Vaccine Raw MaterialsSingapore, January 12, 2026: Hongene Biotech today announced the receipt of a grant from the Gates Foundation to ...

In the years after the 2020 COVID-19 pandemic, it is clear that mRNA as a modality for vaccines and therapeutics is here to stay based on the number of mRNA programs currently in clinical development.

This article is based on a poster originally authored by Harrison H, Glen A , Andrews B, Bayle E, Duncan C, Fyfe M , Guest P, Rausch O , Swain C, Thomas B, Zemla-Brown A, Baric R, Chen Y, Froggatt H, ...

Quantoom’s customers can now access TriLink’s CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions TriLink’s ...